Introduction
The human immunodeficiency virus type 1 (HIV) epidemic remains a major global health problem despite major advances made since the discovery of the virus in 1983 [1] . The HIV infection has been known to be associated to a gastrointestinal pathology since the beginning of the epidemic [2, 3] . Recent studies in HIV-infected individuals and simian models of infection demonstrated that depletion of CD4 + T-cells from gut-associated lymphoid tissues (GALT) occurs very early upon infection [4, 5, 6, 7] . Memory CD4 + T-cells, expressing the HIV coreceptor CCR5, massively infiltrate the GALT and are preferential targets of viral replication and depletion [8, 9] . The alteration of GALT homeostasis in HIV-infected individuals leads to the impairment of mucosal immunity and microbial translocation from the gut, which can drive chronic immune activation [10, 11] . Despite a partial restoration of mucosal immunity in the GALT of individuals receiving long-term antiretroviral therapies (ART) [12, 13] , viral reservoirs persist in different cellular and anatomic compartments and represent a major barrier to HIV eradication [14] .
A small fraction of HIV-infected individuals control disease progression for a long period of time in the absence of ART and are called long-term nonprogressors (LTNPs) or slow progressors [15] . The LTNPs subjects are generally defined as HIV-infected individuals who remain clinically asymptomatic with nondeclining CD4 counts (.500 cells/ml), and undetectable plasma viral loads (,50-75 HIV RNA copies/ml) for .10 years [16] . However, LTNPs are very heterogeneous and include individuals with virological and/or immunological control. Virological controllers (also called ''elite controllers'') are characterized by undetectable plasma viral loads regardless of their CD4 counts, while immunological controllers maintain their CD4 counts in the normal range despite detectable plasma viral loads [15, 16] . Mechanisms involved in the control of disease progression in LTNPs have been linked to host genetic factors controlling the quality of innate and adaptive immunity [17, 18] . The ability of CD8 + T-cells to control HIV replication via cytotoxic and noncytotoxic mechanisms is well documented [19, 20, 21] . However, viral reservoirs persist in LTNPs [22, 23] , pointing out the inability of the immune system to achieve HIV eradication. This is consistent with the finding that the GALT remains an important target of HIV replication in LTNPs with functional alterations in this compartment contributing to slow disease progression [24] . Nevertheless, the existence of a group of HIV-exposed uninfected individuals, in which HIV-specific CD8 + T-cell responses were detected in the cervical mucosa [25] , provides proof that protective immunity against HIV can be mounted under specific conditions. Thus, the mechanisms of immune protection against HIV require further investigations.
HIV infection is initiated by a small viral founder population that undergoes mutations to escape T-cell responses [26, 27, 28] . Limiting viral dissemination from the portal site of entry very early after infection via robust anti-viral mechanisms is of paramount importance to prevent the establishment of a chronic HIV infection [28] . Recent studies using a model of simian immunodeficiency virus (SIV)-infection and in situ visualization techniques demonstrated that SIV-specific CD8
+ T-cells (effectors) are recruited into the vaginal mucosa and lymph nodes in close proximity to SIV-infected CD4
+ T-cells (targets) [29] . The spatial proximity of excess effectors versus target cells appears to be critical for the control of SIV replication and dissemination in vivo [29] . By analogy, the colocalization potential of HIV-specific CD8
+ and CD4
+ T-cells into tissues such as the GALT might determine the extent of viral dissemination and the outcome of disease progression.
Trafficking of peripheral blood T-cells into the GALT is mediated via specific adhesion molecules and chemokine receptors. The integrin a4b7 binds to the mucosal addressin cell adhesion molecule-1 (MadCAM-1) expressed on gut endothelial cells and allows cells to cross the endothelial barrier [30] . The integrin aEb7 binds to the E-cadherin expressed on the basolateral surface of intestinal epithelial cells and contributes to cell retention in the intraepithelial compartment [31] . The CCR6 is important in the recruitment of T-cells into Peyer's Patches [32, 33, 34] , while CCR9 mediates T-cell infiltration into lamina propria [35, 36, 37] . The CCR5 and CXCR3 binding chemokines also regulate infiltration of T-cells into the gut [38, 39] . Previous studies reported the expression of gut-homing molecules on HIV-specific CD8 + or CD4 + T-cells. The HIV-specific CD4 + T-cells express the integrin b7 and CCR5 [40, 41] , while HIV-specific CD8
+ Tcells from the gut express CCR5 and integrin aEb7 [42] . In addition, a fraction of HIV-specific CD4
+ and CD8 + T-cells express CCR6 [43] .
Results from our group and those published by others identified CCR6 as a marker for memory CD4
+ T-cells that are highly permissive to HIV infection in vitro [44, 45] and carry superior levels of integrated HIV-DNA in vivo [44, 45] . Also, we demonstrated that treatment with retinoic acid (RA), a metabolite of vitamin A responsible for the imprinting for gut homing [46, 47] , significantly increased the permissiveness of CCR6 + but not CCR6 2 CD4 + T-cells to HIV replication by acting at entry (CCR5 upregulation) and yet unidentified post-entry levels [48] . Thus, CCR6
+

CD4
+ T-cells may represent sites for active HIV replication into the GALT. The ability of HIV-specific CD8
+ Tcells to be recruited into the GALT in the vicinity of CCR6 + CD4 + T-cells remains unknown and might be predictive of an efficient control of HIV replication in target cells at the portal sites of entry.
In this study, we investigated the potential of total and HIVspecific CD8
+ T-cells to colocalize in excess with CCR6 + CD4 + Tcells and explored the role of the RA pathway in regulating the gut-homing potential of these cells. We report here a decreased frequency of CD8 + and CD4 + T-cells expressing CCR6 in the peripheral blood of HIV-infected subjects regardless of their clinical characteristics of disease progression. In a cohort of HIVinfected subjects with slow disease progression, HIV-specific versus CMV-specific CD4
+ T-cells highly express the gut-homing markers integrin b7, CCR6, and CXCR3, suggesting a link between enhanced permissiveness to infection in HIV-specific CD4
+ T-cells [49] and their gut-homing potential. HIV-specific CD8
+ T-cells also express the gut-homing molecules integrin b7 and CXCR3 but express low levels of CCR6. Thus, HIV-specific CD8 + T-cells may migrate into the gut via integrin b7 and CXCR3 but exhibit a limited potential to colocalize with CD4 + Tcell in certain GALT sites where recruitment is dependent on CCR6 (e.g., Peyer's Patches) [32, 33, 34] . This is consistent with our previous finding that CCR6 +
+ T-cells are major sites for HIV-DNA integration in vivo [44] . Together these results suggest that, in addition to other previously described cellular features (e.g., antiviral properties, poly-functionality, and exhaustion), the colocalization potential of HIV-specific CD4
+ and CD8 + T-cells might represent a new parameter to consider in order to predict the efficacy of anti-HIV responses. Future therapeutic strategies should aim at increasing the colocalization potential of HIVspecific effector and target cells in mucosal tissues for a better control of HIV dissemination from the portal sites of entry.
Materials and Methods
Study subjects
Included in the study were three groups of HIV-infected subjects: (i) treatment-naïve with slow disease progression (SP, slow progressors; n = 14), (ii) recently infected untreated (RI; n = 18), and chronically infected under viral-suppressive anti-retroviral therapy (CI on ART; n = 20). A cohort of n = 13 HIV-uninfected subjects were included in this study as controls. Tables 1, 2, and 3 contain information on the CD4 and CD8 counts, plasma viral loads, and time since infection of SP, RI, and CI on ART HIVinfected subjects, respectively. At the time of leukapheresis, 9/14 SP subjects satisfied the long-term nonprogressor (LTNP) criteria, which include .7 years time since infection, low to undetectable plasma viral load in the absence of ART, and CD4 counts .500 cells/ml [15, 16] , while 5/14 SP subjects had CD4 counts ,500 cells/ml (Table 1) . Among the later group, three subjects (SP 005, 011, 0108) were infected for .19-years and had detectable plasma viral loads, while two subjects (SP 015, 0102) had undetectable plasma viral loads and time since infection .9-years (Table 1) . SP subjects with CD4 counts ,500 cells/ml were not treated as they lacked clinical signs of immunological failure and maintained their plasma viral load ,10 4 HIV RNA copies/ml. CI on ART subjects received various antiviral regimens containing a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, or three nucleoside reverse transcriptase inhibitors, as we previously reported [44] . Plasma viral load was measured using the Amplicor HIV-1 monitor ultrasensitive method (Roche). PBMCs (10 9 -10 10 cells) were collected from HIV-infected and uninfected subjects by leukapheresis, as previously reported [50] . HIV-subjects were recruited via the HIV Primo Infection cohort at the McGill University Health Centre, Royal Victoria Hospital, Montreal, or from the Canadian Cohort of HIV+ Slow Progressors.
Ethics statement
This study using PBMC samples from HIV-infected and uninfected subjects, was conducted in compliance with the principles included in the Declaration of Helsinki. This study received approval from the Institution Review Board of the McGill University Health Center and CHUM-Research Center, Montreal, Canada. All blood donors provided written informed consent for their participation to the study. Antibodies and polychromatic flow cytometry analysis Fluorochrome-conjugated Abs used for polychromatic flow cytometry analysis were CD3-Pacific Blue (UCHT1), CD3-PE/ Cy7 (SK7) CD4-Alexa700 (RPA-T4), CD8 APC-Cy7 (SKI), CCR4-PE/Cy7 (1G1), CXCR3-PE/Cy5 (1C6), CD154-PE/Cy5 (89-76), CCR5-PE (2D7) b7-PE/Cy5 (FIB504), CCR6-PE (11A9) and IFN-c-Alexa700 (B27) (BD Biosciences); CXCR3-FITC (49801) (R&D Systems); b7-PE (FIB504) and IL-17A-PE (ebio64-DEC17) and TNF-a-Pacific Blue (MAB11) (eBioscience). The b7 chain may associate with the a4 chain to form the a4b7 integrin or with the aE chain to form the aEb7 integrin. In previous studies, we demonstrated that the majority of peripheral blood T cells expressed a4 but not the aE chain [48] . Based on this evidence, we can assume the antibody against the b7 chain used in our study identifies the a4b7 dimer.
For extracellular staining, PBMCs were washed with FACS buffer (PBS 1X, 10% FBS (v/v) (Sigma), 0.02% sodium azide (weight/volume)), stained with specific antibodies for 20 minutes at 4uC, washed with FACS buffer, and fixed with a 2% paraformaldehyde buffer. For cell phenotype analysis of antigenspecific T-cells by flow cytometry, 200-5,000 events were acquired using a BD LSRII flow cytometer. A viability stain (Vivid, Invitrogen) was included in the specific staining cocktails to exclude dead cells from our analysis. Results were analyzed using the BD Diva software. Prior to use, all Abs were titrated for an optimal signal to noise ratio. All Abs cocktails were validated by comparing single to multiple staining, and gates were established using fluorescence minus one (FMO), as previously described [44] .
HIV-1 peptide pool preparation
Stimulatory peptides were 15-mers with 11 amino acid overlaps corresponding to HIV-1 clade B consensus Gag (n = 123), Nef (n = 49), and Pol (n = 249) (National Institute of Health (NIH) AIDS Research and Reference Reagent Program, Germantown, MD). Each peptide was diluted in DMSO at 12.5-50 mg peptide/ ml, depending on the peptide solubility and stored at 280uC. These were used for the preparation of peptide pools (50-100 mg peptide/ml), containing 11 to 28 peptides per pool, as described in Table 4 and Table S1 . Pools equivalent to the complete sequence of Nef (100 mg peptide/ml), Gag (100 mg peptide/ml), and Pol (50 mg peptide/ml) proteins were also prepared. Peptide pools were stored at 280uC and used for CD154 assays (10 mg peptide/ ml) and proliferation assays (500 ng peptide/ml) Candida albicans hyphaes culture and lysis Candida albicans hyphaes was used a s positive control for the induction of IL-17 production by T-cells ( Figure S1 ), as previously described [51] . Candida albicans LAM-1 strain was provided by Dr. Louis de Repentigny (University of Montreal, Montreal, Quebec, Canada), as colonies in a Petri dish. From the isolated colonies, the yeast form was cultured overnight at 37uC in Yeast Peptone Dextrose (YPD) medium (BD Bioscience). To induce the transition from the yeasts form to hyphaes, 0.1-0.5610 6 yeasts/ml were cultured in YPD media 20% FBS and incubated for 4 hours at 37uC. The hyphaes generated were washed and resuspended at 2610 6 cellules/100 ml in PBS (GIBCO). Micro glass-beads (SIGMA) were added, and cell lysis was performed using the FastPrep FP120 instrument (Thermo Savant, Carlsbad, CA). Cells Table 3 . Clinical parameters of chronically HIV-infected subjects under long-term viral suppressive ART (CI on ART). were lyzed at a speed of 5 meter/second 4 times for 30 seconds and then placed on ice for 2 minutes; this step was repeated 10 times. Lysates were stored frozen at 220uC. Proliferation assays were performed to determine the optimal immunogenic concentrations of Candida albicans hyphae.
CD154/CD40L assay
To identify antigen-specific CD4
+ T-cells, the CD154/CD40L assay was performed as previously described (89). Briefly, PBMC from HIV-infected subjects were resuspended in RPMI 1640 (GIBCO), 100 units/ml Penicillin (GIBCO), 100 mg/ml Streptomycin (GIBCO), and 2 mM of L-glutamine (RPMI) with 10% FBS (SIGMA) at 10610 6 cells/ml. Cell suspension (200 ml/well) were plated into 96-well plates and stimulated with 1 mg/ml Staphylococcal enterotoxin B (SEB) (Toxin Technology), 5 mg/ml of Cytomegalovirus (CMV) pp65 peptide pool (Miltenyi), 5 mg/ml recombinant HIV-p24 protein (ImmunoDiagnostics, Inc.), or 10 mg/ml of HIV peptide pools (NIAID AIDS Reagent Program) in the presence of 20 ml/well of anti-CD154-PE/Cy5 Abs (BD Biosciences) and 2 mM of monensin (SIGMA) for 16 hrs at 37uC. Cells were then harvested, stained for surface markers with fluorescence-conjugated Abs against CD3, CD4, integrin b7, CCR6, CXCR3, and CCR4, and analyzed by flow cytometry for the expression of homing markers on CD3
CFSE dilution assay
To detect antigen-specific T-cell proliferation, the Carboxy Fluoroscein Succinimidyl Ester (CFSE) dilution assay was performed as previously described [52] . Briefly, PBMC were loaded with 0.5 mM CFSE (Sigma) for 8 minutes at room temperature. The optimal concentration for CFSE was determined by titration for each CFSE lot. Cells were then washed once with PBS and once with RPMI 1640, and then cultured in 5 ml polypropylene tubes (Becton Dickinson) at 2610 6 cells/ml in RPMI with 10% human serum (Gemini). Cells were stimulated with HIV peptide pools in which each peptide was at a concentration of 500 ng/ml, 5 mg/ml recombinant HIV-p24 protein (ImmunoDiagnostics), 25 ng/ml SEB (Toxin Technologies) or 1 mg/ml pp65 CMV peptide pool (Miltenyi) for 6 days at 37uC. Cells were harvested, stained with fluorescence-conjugated Abs against CD3, CD4, integrin b7, CCR6, CXCR3, CCR4, and/or CCR5, and analyzed by flow cytometry for the phenotype 
Intracellular staining for cytokines
CFSE loaded PBMC were stimulated with antigen for 5 days and then restimulated with 50 ng/ml PMA (SIGMA) and 1 mg/ml Ionomycin (SIGMA) in the presence of 10 mg/ml Brefeldin A (SIGMA) for 18 hours. The production of IFN-c, TNF-a, and IL-17A was measured by intracellular staining with appropriate Abs using the BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's protocol.
Statistics
The significance of differences observed between-groups was assessed using Mann-Whitney tests (for unpaired samples) and Paired t-test (for paired samples) as specified in figure legends. The correlation between study variables was assessed using a Spearman correlation test and linear regression models. All statistical analyses were performed using the GraphPad Prism 5 software. P-values ,0.05 were considered significant.
Results
Decreased frequency of CCR6-expressing CD8
+ T-cells in the peripheral blood of HIV-infected subjects with slow and rapid disease progression: We previously identified CCR6 as a marker for memory CD4
+ T-cells being highly permissive to HIV infection in vitro and major sites for HIV-DNA integration in infected subjects [44, 48] . As a consequence, the frequency of circulating CCR6 + CD4 + T-cells is dramatically reduced from the early stages of HIV infection and the normalization of this frequency is not observed under viral suppressive ART [44] . Considering the antiviral properties of CD8 + T-cells [19, 53] , we hypothesized that a robust control of HIV disease progression is dependent on the ability of CD8 + Tcells to co-localize with CCR6-expressing CD4 + T-cells. To test this hypothesis, the expression of CCR6 was first quantified on peripheral blood CD8 + and CD4 + T-cells from HIV-infected subjects with slow and rapid disease progression. The cohort of slow progressors (SP; n = 14) included HIV-infected subjects with a median time since infection of 16 years, median CD4 counts of 670 cells/ml, median CD4 counts of 831 cells/ml, and undetectable or low plasma viral loads (median: 964 HIV RNA copies/ml) in the absence of antiretroviral therapy (ART) ( Table 1 ). The cohort of HIV-infected progressors included recently infected untreated (RI; n = 18; median CD4 counts: 479 cells/ml; median CD8 counts: 855 cells/ml; median plasma viral load: 62,783 HIV RNA copies/ml; median time since infection: 5.7 months) ( Table 2 ) and chronically infected under long-term (.1-year) viral-suppressive ART (CI on ART; n = 20; median CD4 counts: 558 cells/ml; median CD8 counts: 682 cells/ml; median plasma viral load: ,50 HIV RNA copies/ml; median time since infection: 85 months) subjects (Table 3 ). The frequency of CCR6-expressing CD8
+ T-cells and the CD8/CD4 ratios within total and CCR6 + T-cell fractions were compared between HIV-uninfected and the three groups of HIV-infected subjects. The frequency of CCR6-expressing CD8 + and CD4 + T-cells was significantly decreased in RI and CI on ART subjects compared to uninfected controls; unexpectedly, this frequency was also significantly decreased in SP compared to uninfected controls and CI on ART subjects ( Figure 1A-B) . The CD8/CD4 ratios within the total T-cell population were significantly higher in RI (median: 1.4), CI on ART (median: 1.4), and SP subjects (median: 2.3) compared to uninfected controls (median: 0.9) and also in SP compared to CI on ART subjects ( Figure 1C ). This suggests the potential recruitment of excess CD8
+ T-cells in the vicinity of CD4 + T-cells. In contrast, the median CD8/CD4 ratios within the CCR6 + fraction were ,1 in HIV-infected and uninfected subjects, with no significant differences between RI, CI on ART, and SP subjects ( Figure 1D ). No significant correlations were found between CD4 counts or plasma viral loads and all four parameters investigated in Figure 1 within the three HIV-infected groups (data not shown). These results demonstrate an alteration in the frequency of CCR6-expressing CD8
+ and CD4 + T-cells in HIVinfected subjects regardless of their clinical characteristics of disease progression. These results suggest the inability of CD8
+ Tcells to be recruited in excess in the proximity of CCR6 + CD4 + Tcells, and this even in subjects with slow disease progression. CD4 + T-cells specific for HIV versus CMV preferentially express gut-homing markers: HIV preferentially infects HIV-specific CD4
+ T-cells, while CMV-specific CD4 + Tcells are relatively resistant to infection in vivo [41, 49, 54] . This coincides with the fact that HIV-specific CD4
+ T-cells express higher levels of the HIV CCR5 coreceptor and produce lower levels of CCR5 binding chemokines than do CMV-specific CD4 + T-cells [41, 49, 54] . We hypothesized that differences in viral permissiveness between HIV-specific versus CMV-specific CD4 + T-cells are also related to their distinct ability to home into anatomic sites of active viral replication, such as the GALT. To test this hypothesis, we investigated the gut-homing potential on CD4 + T-cells specific for HIV versus CMV. The SEB superantigen is known to induce polyclonal T-cell activation [52] and was used as a positive control. The tissue-specific homing molecules studied were integrin b7 for the migration across the GALT endothelium [30, 39, 46] , CCR6 for the migration into the GALT Peyer's Patches [33, 55] , CXCR3 for the migration into inflammatory sites, including the GALT [30, 39, 46, 56] , and CCR4 for the migration into the skin [57] . Experiments were performed with PBMC from seven HIV-infected treatment-naïve subjects with slow disease progression (Table 1) , because they exhibited relatively high frequencies of HIV-specific CD4 + and CD8 + Tcells (Table 4 and Table S1 ). This choice is also justified by the fact that the frequency of CD4 + and CD8 + T-cells expressing CCR6 is also altered in the peripheral blood of SP subjects compared to uninfected controls (Figure 1) .
In a first experimental approach, antigen-specific CD4 + T-cells were identified based on their expression of CD154 (CD40 ligand, CD40L) using flow cytometry analysis ( Figure S1A ), as previously described by others [58] . The PBMCs from HIV-infected individuals were screened for the ability to respond to an antigen panel that included HIV Nef (n = 3), Gag (n = 6) and Pol (n = 11) overlapping peptide pools, HIV-p24 recombinant protein, SEB, and CMV-pp65 recombinant protein (Table S1) . The PBMCs were then stimulated with the most immunogenic antigenic panel and the expression of integrin b7, CCR6, CXCR3, and CCR4 was analyzed on antigen-specific CD154 + CD4 + T-cells by polychromatic flow cytometry ( Figure S1A-B) . The phenotype of CD154 + CD4 + T-cells specific for different HIV peptide pools was highly heterogeneous within the same donor. Also, inter-donor variations were observed in the expression of homing molecules on CD154 + CD4 + T-cells, even those specific for the same HIV peptide pool ( Figure S1C ). Regardless of this heterogeneity, statistical analysis of homing molecule expression demonstrated that HIV-specific compared to CMV-specific CD154 +
CD4
+ Tcells expressed significantly higher levels of the integrin b7 ( Figure S1D ). In addition, HIV-specific compared to SEB-specific T-cells displayed increased expression of the integrin b7, CCR6, CXCR3, and CCR4 ( Figure S1D ). These results demonstrate that HIVspecific CD154
+ CD4 + T-cells distinguish from cells of other antigenic specificities (CMV, SEB) by their high expression of both gut-homing markers integrin b7 and CCR6.
In a second experimental approach, antigen-specific CD4 + Tcells were identified based on their proliferation potential (CFSE low phenotype) using the CFSE dilution assay (Figure 2A) , as previously described [52] . The PBMCs from HIV-infected individuals were screened for the ability to respond to an antigen panel that included HIV Nef (n = 3), Gag (n = 6) and Pol (n = 11) overlapping peptide pools, HIV-p24 recombinant protein, SEB, and CMV-pp65 recombinant protein ( Table 4) . The PBMCs were then stimulated with the most immunogenic antigenic panel and the expression of integrin b7, CCR6, CXCR3, and CCR4 was quantified on CFSE low CD4 + T-cells by polychromatic flow cytometry ( Figure 2B ). Similar to data obtained on HIV-specific CD154 + CD4 + T-cells ( Figure S1C ), inter-and intra-donor variations were observed in the phenotype of CFSE low CD4 + Tcells specific for different HIV peptide pools ( Figure 2C ). CXCR3 was expressed by the majority of antigen-specific cells, while the expression of integrin b7, CCR6 and CCR4 was limited to a fraction of cells ( Figure 2C ). The CD4 + T-cells proliferating in response to the HIV NefGagPol peptide pool versus CMV from matched donors expressed significantly higher levels of integrin b7, CCR6, and CXCR3, with not significant differences regarding CCR4 expression ( Figure 2D ). The same trend was observed when CD4 + T-cells specific for all HIV peptide pools were compared with those specific for CMV from five different donors ( Figure  S2A ). The HIV-specific CD4
+ T-cells identified as CD154 + versus CFSE low cells differed in the expression of homing receptors; these differences were observed when cells were stimulated with distinct (Nef versus Gag, respectively) or the same HIV antigenic pools (HIV-p24) ( Figure S1C and Figure 2C) . However, the expression at high levels of both integrin b7 and CCR6 remained a unique feature of HIV-specific CD4
+ T-cells when compared to CMVspecific cells ( Figures S1D and S2A , and Figure 2D ). This unique particularity of HIV-specific CD4
+ T-cells may confer them the ability to migrate into the GALT, a major site of HIV replication in vivo [8, 59] .
CCR6 is a well established marker for Th17 and Th1Th17 cells with a CCR4
+ CCR6 + and CXCR3 + CCR6 + phenotype [60] . Our results demonstrated that only a minority of CFSE low HIV-specific 
+ T-cells produced IL-17, while a larger fraction produced IFN-c and TNF-a ( Figure S3 ). These results indicate that HIVspecific CD4
+ T-cells exhibit a Th1Th17 polarization profile. We previously demonstrated that a Th1Th17 profile is favorable to active HIV replication in vitro [44] . Therefore, HIV-specific cells from SP subjects may be highly permissive to HIV, as previously demonstrated in HIV progressors [41, 49, 54] .
The colocalization potential of HIV-specific CD4 + and CD8 + T-cells is mediated by the integrin b7 but not CCR6: The antiviral properties of CD8 + T-cells are well characterized [19, 20, 21] and depend on their ability to colocalize in excess with target cells, such as CD4
+ T-cells [28, 29] . We next investigated the expression of gut-homing molecules on HIVspecific CD8
+ T-cells in order to evaluate their ability to colocalize with HIV-specific CD4 + T-cells for an efficient control of HIV replication in vivo. In preliminary experiments, we demonstrated that the majority of CD8 + T-cells exhibited a CD3 + CD4 2 phenotype (data not shown). Antigen-specific CD8 + T-cells were identified as CFSE low cells ( Figure 3A ) and tested for their expression of the integrin b7, CCR6, CXCR3, and CCR4 ( Figure 3B ). Similar to antigen-specific CD4 + T-cells ( Figure 2C ), the expression of the homing receptors on CFSE low CD8 + T-cells was subject to inter-donor variations ( Figure 3C ). Despite this heterogeneity, HIV NefGagPol -specific versus CMV-specific CFSE low CD8
+ T-cells from matched donors expressed significantly higher levels of integrin b7, while no significant differences were observed in the levels of CCR6, CXCR3, and CCR4 expression ( Figure 3D ). The same results were observed when CD8 + T-cells specific for all HIV peptide pools were compared with those specific for CMV ( Figure S2B ). These results suggest an increased ability of HIVspecific versus CMV-specific CD8 + T-cells to migrate via integrin b7 into the GALT, which is likely a site for the initial priming of HIV-specific T-cells.
To further investigate the colocalization potential of HIVspecific CD4
+ and CD8 + T-cells, the frequency of cells expressing gut-homing molecules was compared between matched CD4 + and CD8
+ T-cells proliferating in response to specific HIV peptide pools. Results depicted in Figure 4A show that HIV-specific CD8 + compared to CD4 + T-cells express significantly higher levels of integrin b7, lower levels of CCR6 and CCR4, and similarly high levels of CXCR3. Spearman correlation and linear regression models were applied and demonstrated a positive correlation between the frequency of HIV-specific CD4 + and CD8 + T-cells expressing the integrin b7 and CXCR3; this correlation was not observed for CCR6 and CCR4 ( Figure 4B ). Moreover, there was a positive correlation between the frequency of HIV-specific CD4 + and CD8
+ T-cells co-expressing the integrin b7 and CXCR3 ( Figure 4C) . Furthermore, the b7 + CXCR3 + phenotype appears to be a unique feature of HIV-specific T-cells since the frequency of b7 +
CXCR3
+ cells was significantly higher in HIV NefGagPol -specific versus CMV-specific CD4 + and CD8 + T-cells from four matched SP subjects ( Figure S2C ). The proliferation of CD8 + compared to CD4
+ T-cells in response to a specific HIV peptide pool was significantly higher in all five HIV-infected subjects ( Figure 4D) , with median CD8/CD4 ratios of 3.2, 2.3, 4.1, 5.6, and 2.8 in SP subjects 001, 006, 007, 011, and 015, respectively (data not shown). These results suggest that a significant fraction of HIVspecific CD8 + T-cells may colocalize with CD4 + T-cells (at high CD8/CD4 ratios) in certain anatomic sites of the GALT where homing depends on integrin b7 and CXCR3. In contrast, HIVspecific CD8
+ T-cells express low levels of CCR6 and CCR4 and thus may be impaired in their ability to colocalize and control viral replication in CCR6 + CCR4 + CD4 + T-cells, such as Th17 cells [51] which are highly permissive to infection [44, 45] . Thus, the low expression of CCR6 on CD8
+ T-cells may reflect their limited ability to control HIV replication in CD4
+ T-cells from certain GALT sites such as the Peyer's Patches, where homing depends on CCR6 [32, 33, 34] .
The retinoic acid pathway regulates expression of integrin b7 but not CCR6 and CCR5 on HIV-specific Tcells: The imprinting for gut-homing is regulated at least in part by RA, a derivate of vitamin A metabolism produced by the intestinal dendritic cells [46, 47] . Of note, exposure of CD4 + Tcells to RA upregulates integrin b7 and CCR5 expression and renders them highly permissive to HIV replication [61, 62] . Here, we investigated whether RA can be used to manipulate the colocalization potential of HIV-specific CD4 + and CD8 + T-cells via integrin b7 and CCR6. With this in mind, PBMC from SP subjects were exposed to the HIV NefGagPol peptide pool, SEB, or CMV in the presence or absence of all-trans RA (ATRA) or the RA antagonist LE540. In preliminary experiments, we demonstrated that at physiological dose (10 nM [61, 63] ), ATRA did not have any significant effect on cell proliferation, while LE540 at 1 mg/ml [64] decreased integrin b7 expression on SEB-specific Tcells without interfering with cell viability (data not shown). The expression of integrin b7, CCR5, and CCR6 was quantified on CFSE low T-cells by multicolor flow cytometry. Exposure to ATRA and LE540 led to a significant increase and decrease, respectively, in the integrin b7 expression on CD4 + T-cells specific for HIV-, SEB, and CMV and also on CD8 + T-cells specific for HIV and SEB ( Figure 5A ). The ATRA also increased expression of CCR5 on SEB-specific and CMV-specific but not on HIV-specific T-cells ( Figure 5B ), where levels of CCR5 expression were higher, although not statistically significant due to donor-to-donor variability, compared to those on SEB-specific and CMV-specific T-cells (Paired t-Test p = 0.04 and p = 0.1, respectively). In contrast, ATRA and LE540 treatment did not interfere with the expression of CCR6 on antigen-specific CD4 + or CD8 + T-cells ( Figure 5C ). These results demonstrate that the RA pathway regulates the expression of integrin b7 but does not interfere with CCR5 and CCR6 expression on HIV-specific CD4
+ and CD8 + Tcells.
To gain more insights into the regulation of trafficking potential of HIV-specific T-cells, we studied the effects of RA and LE540 on the frequency of HIV-specific T-cells with a b7
+ and b7
+ phenotype. The CD4 + and CD8 + T-cells proliferating Figure 2 . Preferential gut-homing potential of HIV-specific versus CMV-specific CD4 + T-cells. PBMC from SP subjects were loaded in CFSE (0.5 mM) and stimulated with different HIV Nef, Gag, Pol peptide pools (500 ng/ml), recombinant HIV-p24 (5 mg/ml), SEB (25 ng/ml), or the recombinant CMV-pp65 peptide pool (1 mg/ml) for 6 days at 37uC. Antigen-specific T-cells were identified as CFSE low cells, as previously described [52] . Cells were stained with a cocktail of fluorescence-conjugated CD3, CD4, integrin b7, CCR6, CXCR3, and CCR4 Abs and analyzed by polychromatic flow cytometry for (A) the frequency of CFSE . Retinoic acid activation pathway regulates integrin b7 expression on HIV-specific T-cells. PBMC from SP subjects were loaded in CFSE (0.5 mM) and stimulated with HIV Nef-Gag-Pol peptide pool (500 ng/ml), SEB (25 ng/ml), or the recombinant CMV-pp65 peptide pool (1 mg/ml) for 6 days at 37uC in the presence or absence of all-trans-retinoic acid (ATRA; 10 nM) or the RA antagonist LE540 (1 mg/ml). Cells were stained with a cocktail of fluorochrome-conjugated CD3, CD4, integrin b7, CCR5 or CCR6 Abs and analyzed for the expression of (A) integrin b7, (B) CCR5, and (C) CCR6 on CFSE low CD4 + and CD8 + T-cells specific for SEB, CMV, and HIV antigens. Experiments were performed with cells from four SP subjects (mean6SD in response to HIV differed from CMV-or SEB-specific T-cells by an increased frequency of b7 + CCR5 + T-cells ( Figure 6A and C). The pool of HIV-specific CD4 + T-cells included higher frequencies of cells with a b7
+ phenotype compared to cells specific for CMV or SEB, while CD8 + T-cells specific for HIV, CMV, or SEB included very low frequencies of b7
+ T-cells ( Figure 6B ). Exposure to ATRA and LE540 led to a significant increase and decrease, respectively, in the frequency of HIVspecific CD4
+ and CD8 + T-cells with a b7 Figure 6D ). Since ATRA does not modulate CCR5 expression on HIV-specific cells (Figure 5C ), the increase in the frequency of b7 +
CCR5
+ cells ( Figure 6D ) is likely due to the upregulation of integrin b7 expression on existing CCR5
+ T-cells. Finally, ATRA and LE540 treatment had no significant effects on the frequencies of HIV-specific CD4 + or CD8 + T-cells with a b7 + CCR6 + phenotype ( Figure 6E ). These results provide evidence that ATRA may be used to enhance recruitment of HIV-specific CD4 + and CD8
+ T-cells across the intestinal endothelium via the integrin b7. In contrast, ATRA does not interfere with CCR6 expression and cannot facilitate the in situ colocalization of CD8
+ T-cells with CCR6 + CD4 + T-cells.
Discussion
The GALT is a major site for HIV replication in vivo [8, 59] , with HIV-specific CD4
+ T-cells being highly permissive to infection [49] . The recruitment of effector CD8
+ T-cells in the proximity of target CD4
+ T-cells is a prerequisite for an efficient control of viral replication in vivo [29, 65] . In this study, we investigated the potential of HIV-specific CD8
+ T-cells to colocalize in excess with CD4
+ T-cells in the GALT and explored the role of the retinoic acid (RA) activation pathway in regulating this process. We demonstrated that a large fraction of HIV-specific CD4 + and CD8 + T-cells express the gut-homing molecules integrin b7 and CXCR3 while CCR6, a marker of HIV permissiveness in CD4
+ T-cells [44, 48] , was expressed at high and low levels on HIV-specific CD4
+ and CD8 + T-cells, respectively. We also demonstrated that RA upregulated integrin b7 expression but did not affect CCR6 expression. Our data support a model in which HIV-specific CCR6 + CD4 + T-cells escape the antiviral control of CD8 + T-cells in certain GALT sites (e.g., Peyer's Patches) where migration is dependent on CCR6 [32, 33, 34] (Figure 7) . Considering the critical role played by CCR6 + Th17 cells in mucosal immunity [66] , uncontrolled HIV replication in these cells likely leads to dramatic alterations of mucosal immunity and microbial translocation [13, 59, 67, 68, 69] . These observations were made in a cohort of SP subjects with a median time since infection 16 years. Whether CD8 + T-cells colocalize in excess with CCR6 + CD4 + T-cells for an efficient control of HIV replication in SP subjects during the first years of infection or in HIV-exposed uninfected individuals remains to be determined.
Our initial hypothesis was that the colocalization potential of CD8 + T-cells with CCR6 + CD4 + T-cells was altered in HIVinfected subjects with disease progression but not in slow progressors (SP). To test this hypothesis, the expression of CCR6 was quantified on peripheral blood CD8 + and CD4 + T-cells from SP subjects and two other cohorts of HIV progressors, recently infected untreated (RI) and chronically infected under viral suppressive ART subjects (CI on ART). Unexpectedly, we found an alteration in the frequency of CCR6-expressing CD8 + and CD4
+ T-cells in HIV-infected subjects regardless of their clinical characteristics of disease progression. This suggested the inability of CD8
+ T-cells to be recruited in excess in the proximity of CCR6 + CD4 + T-cells, and this even in subjects with slow disease progression. This is consistent with studies reporting immunological alterations related to HIV persistence in CD4 + T-cells and chronic immune activation in SP subjects, especially after many years of infection in the absence of ART [23, 24, 70, 71] .
According to the paradigm of tissues-specific homing, effector memory T-cells are imprinted with the ability to recirculate into peripheral tissues where the initial antigen encounter took place [37, 46, 56, 72] . A specific combination of adhesion molecules and chemokine receptors regulate the multi-step process of tissuespecific homing of T-cells [73, 74] . Also, local presentation of antigens by endothelial cells contribute to the recruitment of Tcells into specific sites [75] . In this study, we demonstrated that HIV-specific CD154 + CD4 + T-cells express molecules regulating migration into the GALT (integrin b7, CCR6, CXCR3) and skin (CCR4). Considering the fact that the GALT [59, 69] but not the skin are sites of HIV replication in vivo, this broad homing potential of HIV-specific CD154 + CD4 + T-cells was unexpected and inconsistent with the paradigm of tissue-specific homing of pathogen-specific T-cells. This exception from the rule is not unique. In fact, T-cells induced upon subcutaneous yellow fever immunization have a dynamic migration program and home into multiple distal tissues, including the GALT [76] .
CD154 was proposed as a surrogate marker for the identification of cytokine-producing T-cells in response to an antigenic stimulation [58] . However, we found a differential expression of homing molecules on recently activated CD154 + compared to proliferating CD4
+ T-cells (CFSE low ) in response to HIV, SEB, or CMV. The skin-homing receptor CCR4 was highly expressed on CD154 + compared to CFSE low CD4 + T-cells specific for HIV and CMV. This is consistent with the paradigm that T-cells are originally imprinted with a skin-homing potential that is lost during the process of differentiation into specialized Ag-specific cells [46] . Also, the expression of CCR6 was higher on CMVspecific CD154
+ compared to CFSE low CD4 + T-cells, while the integrin b7 expression was lower on SEB-specific CD154 + compared to CFSE low CD4 + T-cells. The finding that some antigens induced either CD154 + or CFSE low CD4 + T-cells but not both suggests that CD154 expression does not predict the ability of a cell to proliferate. Accordingly, CD154
+ CD4 + T-cells were mainly triggered by HIV Nef peptide pools, while CFSE low CD4 + Tcells were selectively induced by HIV Gag peptide pools (Table 4  and Table S1 ). Thus, HIV-specific CD154 + and CFSE low CD4
+ T-cells exhibit distinct homing potential and antigenic specificity and therefore may represent different stages of CD4 + T-cell differentiation with distinct roles in antiviral immunity. The molecular determinism underlying these differences remains unclear but might be related to the anatomic site of original antigenic priming.
The HIV establishes a persistent infection by mechanisms that are not clearly understood, and viral eradication is not achieved under current antiretroviral therapies [14, 77] . The CD4 + T-cells play a critical role in HIV pathogenesis [77] . The HIV-specific compared to CMV-specific CD4
+ T-cells are preferentially infected with HIV in vivo [49] . This is because HIV-specific CD4
+ T-cells express high levels of the HIV coreceptor CCR5 [41] and produce low levels of CCR5 binding chemokines and therefore fail to protect themselves from infection in an autocrine manner [54] . Consistent with the evidence that the GALT is a major site of HIV replication [59, 69] , we observed that HIVspecific compared to CMV-specific CD154 +
CD4
+ T-cells expressed at high levels both gut-homing molecules integrin b7 and CCR6. We also observed increased expression of integrin b7 and CCR6 on CD4
+ T-cells proliferating in response to HIV compared to CMV antigens. In addition to their role in guthoming, the integrin b7 was identified as a new HIV-gp120 binding receptor [61, 62] , and its expression on HIV-specific CD4 + T-cells might favor HIV binding on these cells and viral dissemination from the portal sites of entry. The CCR6 is a marker for memory CD4 + T-cells with a Th17 and Th1Th17 lineage polarization profile [51] . We found that a small fraction of HIV-specific cells produced IL-17, with the majority of cells producing IFN-c and TNF-a. Thus, HIV-specific CD4
+ T-cells exhibit a Th1Th17 polarization profile. Indeed other studies demonstrated that very few HIV-specific CD4
+ T-cells produce IL-17 [78] . Considering our previous findings that HIV replicates actively in T-cells with a Th1Th17 polarization profile [44] , these results suggest that HIV-specific CD4
+ T-cells in SP subjects are also permissive to infection. Consistent with this prediction, the expression of the HIV co-receptor CCR5 was relatively high on HIV-specific CD4
+ T-cells from SP subjects. This may render them extremely permissive to infection and may explain why some of the SP subjects begin loosing their CD4 counts, especially after many years of infection in the absence of ART [16] . Hence, the expression of integrin b7, CCR6, and CCR5 represents a unique ''signature'' for HIV-specific T-cells. The relationship between imprinting for gut-homing and viral permissiveness was recently demonstrated for adenovirus serotype 5 (AD5)-specific CD4
+ Tcells generated upon AD5-HIV vaccination (STEP trial), as cells exhibited an integrin a4b7 +
CCR5
+ phenotype and high susceptibility to HIV infection [79] . The molecular mechanisms that control homing potential of HIV-specific T-cells are likely related to the cellular/tissue environment in which these cells initially encountered antigen. Indeed, the GALT dendritic cells produce RA, which is known to trigger integrin a4b7 expression and upregulate CCR5 expression on T-cells [47, 48, 61] . Similarly, the GALT environment is rich in Th17 polarizing cytokines (TGF-b, IL-1, IL-6) [51, 80, 81] that may trigger CCR6 expression on HIVspecific CD4
+ T-cells. The CD8
+ T-cells control HIV replication in target cells via cytotoxic and non-cytotoxic mechanisms [19, 20, 21] . Recent studies using visualization techniques demonstrated that recruitment of excess viral-specific effectors in the vicinity of target cells is critical for the control of viral replication and disease progression in an SIV model of infection [29] . Our results reveal that matched HIV-specific CD8
+ and CD4 + T-cells may colocalize to anatomic sites where recruitment is mediated by integrin b7, CXCR3 and/ or CCR5 ( Figure 7A ). The expression of integrin b7 on both HIVspecific CD8
+ and CD4 + T-cells supports the idea that these cells are primed with the antigen within the GALT, where they are likely exposed to factors that imprint cells with a gut-homing potential [46, 47] . The CXCR3 is responsible for leukocyte migration into the inflammatory sites, including the gut [56] . Of note, a decreased frequency of CXCR3 + CD8 + T-cells was reported in advanced HIV-1 infection that might contribute to cytotoxic T-lymphocyte dysfunction [82] . In our SP cohort, HIVspecific T-cells expressed maximal levels of CXCR3, and this suggests their functional competence in vivo. In contrast, we observed that CCR6 was expressed at high levels on HIV-specific CD4
+ but not CD8 + T-cells. The low expression of CCR6 on HIV-specific CD8 + T-cells was consistent with the decreased frequency of memory CCR6 +
CD8
+ T-cells in the peripheral blood Figure 6 . Retinoic acid upregulates the frequency of HIV-specific T-cells with a b7
PBMC from SP subjects were loaded in CFSE (0.5 mM) and stimulated as in Figure 5 . Cells were stained with a cocktail of fluorochrome-conjugated CD3, CD4, and integrin b7, and CCR5 or CCR6 Abs. CFSE low CD4 + and CD8 + T-cells specific for SEB, CMV, and HIV Nef-Gag-Pol peptide pool were analyzed for the coexpression of (A) integrin b7 and CCR5 and (B) integrin b7 and CCR6. + and CD8 + T-cells into the GALT. The control of viral replication is dependent on the in situ colocalization of excess effector versus target cells [28] . Given the results included in Figures 1-6 of the present manuscript, we propose a model where (A) HIV replication in CD4
+ T-cells may be controlled by CD8 + T-cells in certain GALT sites (e.g., lamina propria), where recruitment is dependent on integrin b7, CXCR3 and CCR5 because of an increased ratio between HIV-specific CD8 + and CD4 + T-cells. In contrast, (B) HIV-specific CD4 + T-cells recruited into other GALT sites via CCR6 (e.g., Peyers's Patches) may escape the CD8 + T-cell-mediated antiviral control due to a limited CCR6-dependent colocalization potential of CD4 + and CD8 + T-cells. This model is in line with our previous findings that CCR6 +
CD4
+ T-cells harbor the highest levels of integrated HIV-DNA in vivo [44] and suggests that novel therapeutic strategies aimed at increasing CCR6 expression on CD8 + T-cells may lead to a better control of HIV replication in CCR6 
+ T-cells are highly permissive to HIV-DNA integration in vivo [44] . The escape of CCR6 + CD4 + T-cells from the non-cytotoxic antiviral control by CD8
+ T-cells may also explain the preferential depletion of these cells during disease progression [44] , likely via a virus-induced toxicity mechanism [83] .
Several previous studies demonstrated that HIV-specific CD8 + T cells from SP subjects are efficient in controlling viral replication ex vivo [15, 16, 19] . This is consistent with our observations in vitro that HIV replication in antigen-stimulated PBMC from the seven SP subjects was controlled (undetectable HIV-p24 levels, as quantified by ELISA), likely by CD8 + T-cells (Ancuta, unpublished observations). However, the situation in vivo may be different. Our results support a model in which the low expression of CCR6 on HIV-specific CD8
+ T-cells is exploited by HIV-1 for its efficient replication in CCR6 + CD4 + T-cells in some GALT sites such as the Peyer's Patches ( Figure 7B ). In this context, it is of interest to identify ways to increase the ability of HIV-specific CD8 + T-cell to colocalize with HIV-specific CD4 + T-cells. We found that RA increased the expression of integrin b7 on T-cells specific for HIV, CMV and SEB and the frequency of T-cells specific for CMV and SEB with a b7 + T-cells and remain to be identified.
Together, these results suggest the ability of HIV-specific CD8 + and CD4 + T-cells to colocalize into the GALT (e.g., lamina propria) via integrin b7, CCR5, and CXCR3 and reveal a limited potential of HIV-specific CD8 + T-cells to migrate into other GALT sites (e.g., Peyer's Patches), where recruitment is dependent on CCR6 [32, 33, 34] . Studies on gut biopsies are required to validate our proposed model (Figure 7) , which is consistent with the preferential permissiveness of CCR6 + CD4 + T-cells to HIV infection in vivo [44] . In this context, understanding molecular mechanisms regulating CCR6 expression on HIV-specific CD8 + T-cells, together with the expression of the CCR6 ligands into the GALT, is of paramount importance for the design of new therapeutic strategies aimed at HIV eradication. However, caution must be taken when designing such strategies to avoid an increased recruitment of HIV targets at the portal sites of mucosal entry. Finally, studies evaluating the functionality of the immune system in response to ART and vaccination may gain in physiological relevance if they consider monitoring the in situ colocalization potential of HIV-specific CD8
+ and CD4 + T-cells as a new correlate of protection. Figure S1 The HIV-specific versus CMV-specific CD154 +
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CD4
+ T-cells preferentially express a gut-homing potential. PBMC from SP subjects were stimulated with different HIV Nef, Gag, Pol peptide pools (10 mg/ml), recombinant HIVp24 protein (5 mg/ml), SEB (1 mg/ml), or CMV-pp65 peptide pool (5 mg/ml) for 18 hours at 37uC in the presence of fluorescence conjugated anti-CD154-PE/Cy5 Abs (20 ml/2610 6 cells/0.2 ml/ well). Antigen-specific T-cells were identified as CD154
+ cells, as previously described [58] . Cells were harvested, stained with a cocktail of fluorochrome-conjugated CD3, CD4, and b7 integrin, CCR6, CXCR3, or CCR4 Abs and analyzed by polychromatic flow cytometry for (A) the expression of CD154 on CD3 + T-cells exhibit a Th1Th17 polarization profile. PBMCs from SP subjects were loaded in CFSE (0.5 mM) and stimulated with different HIV Nef, Gag, Pol peptide pools (500 ng/ml), recombinant HIV-p24 (5 mg/ ml), SEB (25 ng/ml), a peptide pool spanning the CMV pp65 protein (1 mg/ml), or C. albicans hyphae (25 ml of protein lysate) for 5 days at 37uC and further stimulated with PMA (50 ng/ml) and Ionomycin (1 mg/ml) in the presence of Brefeldin A (10 mg/ml) for 18 hours at 37uC. Cells were stained on the surface with CD3 and CD8 Abs as well as intracellularly with IFN-c, TNF-a, and IL-17 Abs and then analyzed by polychromatic flow cytometry for the expression of cytokines in CD3 + CD8 2 (referred as CD4 + T-cells) cells. Shown is (A) the gating strategy for CD4 + T-cells identification and (B) representative dot plots of IFN-c, TNF-a, and IL-17 production by HIV-specific and C. albicans-specific CD4 + T-cells. (C) Shown is the intracellular expression of cytokines by CFSE low CD4 + T-cells specific for SEB, CMV, C. albicans, and different HIV peptide pools in five different SP subjects. (TIF) + T-cells responses using the CD154 co-culture assay. To identify antigen-specific CD4 + T-cells, the CD154/CD40L assay was performed as previously described (89). To this aim, PBMC from five HIV-infected SP subjects were stimulated with SEB (1 mg/ml), CMV-pp65 peptide pool (5 mg/ml), recombinant HIV-p24 protein (5 mg/ml), or HIV peptide pools (10 mg/ml) in the presence of anti-CD154-PE/Cy5 Abs (20 ml/well) and monensin (2 mM) for 16 hrs at 37uC. Cells were then harvested, stained for surface markers with fluorescence-conjugated Abs against CD3, CD4, integrin b7, CCR6, CXCR3, and CCR4, and analyzed by flow cytometry for the expression of homing markers on CD3 + CD4 
